γ-Cyclodextrin hydrogel for the sustained release of josamycin for potential ocular application
Glaucoma is the leading cause of blindness worldwide. However, its surgical treatment, in particular via trabeculectomy, can be complicated by fibrosis. In current clinical practice, application of the drug, Mitomycin C, prevents or delays fibrosis, but can lead to additional side effects, such as b...
Saved in:
Published in | Drug delivery Vol. 31; no. 1; p. 2361168 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Taylor & Francis Ltd
01.12.2024
Taylor & Francis Taylor & Francis Group |
Subjects | |
Online Access | Get full text |
ISSN | 1071-7544 1521-0464 1521-0464 |
DOI | 10.1080/10717544.2024.2361168 |
Cover
Summary: | Glaucoma is the leading cause of blindness worldwide. However, its surgical treatment, in particular via trabeculectomy, can be complicated by fibrosis. In current clinical practice, application of the drug, Mitomycin C, prevents or delays fibrosis, but can lead to additional side effects, such as bleb leakage and hypotony. Previous
drug screening and
testing has identified the known antibiotic, josamycin, as a possible alternative antifibrotic medication with potentially fewer side effects. However, a suitable ocular delivery mechanism for the hydrophobic drug to the surgical site does not yet exist. Therefore, the focus of this paper is the development of an implantable drug delivery system for sustained delivery of josamycin after glaucoma surgery based on crosslinked γ-cyclodextrin. γ-Cyclodextrin is a commonly used solubilizer which was shown to complex with josamycin, drastically increasing the drug's solubility in aqueous solutions. A simple γ-cyclodextrin crosslinking method produced biocompatible hydrogels well-suited for implantation. The crosslinked γ - cyclodextrin retained the ability to form complexes with josamycin, resulting in a 4-fold higher drug loading efficiency when compared to linear dextran hydrogels, and prolonged drug release over 4 days. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Supplemental data for this article can be accessed online at https://doi.org/10.1080/10717544.2024.2361168. |
ISSN: | 1071-7544 1521-0464 1521-0464 |
DOI: | 10.1080/10717544.2024.2361168 |